RA Capital Healthcare Fund LP 4

What Happened RA Capital Management, L.P. (a reported 10% owner) was granted a derivative award on 2026-06-29 covering 70,284 shares of Climb Bio (CLYM) at a reported acquisition price of $0.00. The filing shows this is an option-based grant (derivative), not an open-market purchase or sale. The reporting persons disclaim beneficial ownership of the option and the underlying common stock.

Key Details

• Transaction date: 2026-06-29; Form filed: 2026-07-01 (timely).
• Award: 70,284 shares (derivative option) reported at $0.00 acquisition price.
• Vesting: Shares underlying the option vest in equal monthly installments from June 29, 2026 through the third anniversary, subject to continued service.
• Beneficial ownership: Adviser and related entities disclaim beneficial ownership; Breanna Celebi holds the option for the benefit of the funds/accounts and must turn over net cash/stock received to the Adviser to offset advisory fees.
• Shares owned after transaction: Not reported as beneficially owned by the reporting persons (disclaimed).

Context This is an institutional option grant tied to service/vesting rather than an outright purchase of stock. Breanna Celebi, an analyst at the Adviser who serves on Climb Bio’s board, holds the option for the funds and account managed by RA Capital; the reporting entities disclaim direct beneficial ownership. For retail investors, grants like this are routine compensation or incentive arrangements and do not by themselves signal a personal purchase or sale by the institutional holder.